Analytical Approaches for the Determination of Buprenorphine, Methadone and Their Metabolites in Biological Matrices

Xiaoyue Shan †, Chengjian Cao † and Bingsheng Yang *

Hangzhou Occupational Disease Prevention and Treatment Hospital, Hangzhou 310014, China
* Correspondence: yangbingshengzfy@126.com; Tel.: +86-571-851-31787
† These authors contributed equally to this work.

Abstract: The abuse of buprenorphine and methadone has grown into a rising worldwide issue. After their consumption, buprenorphine, methadone and their metabolites can be found in the human organism. Due to the difficulty in the assessment of these compounds by routine drug screening, the importance of developing highly sensitive analytical approaches is undeniable. Liquid chromatography tandem mass spectrometry is the preferable technique for the determination of buprenorphine, methadone and their metabolites in biological matrices including urine, plasma, nails or oral fluids. This research aims to review a critical discussion of the latest trends for the monitoring of buprenorphine, methadone and their metabolites in various biological specimens.

Keywords: analytical methods; methadone; buprenorphine; biological matrices

1. Introduction

Opioid use disorder (OUD) is a serious public health issue [1,2]. The disorder is associated with high morbidity and mortality rates as well as an increased risk and cost of crime [3]. Approximately 26.8 million people were estimated to have OUD globally in 2016 and at least 100,000 overdose deaths are reported each year [4]. The US Food and Drug Administration (FDA) have approved buprenorphine (BUP) and methadone (MTD) for the treatment of OUD; these medications have great efficacy and can save lives [5]. BUP and MTD are synthetic opioids widely employed as analgesics to control and treat pain [6]. They are also effectively applied as medications in the treatment of OUD patients [7].

BUP is a semi-synthetic opioid possessing partial u-type agonist and k-type antagonist opioid activity [8]. As an analgesic, BUP is about 25–50 times more potent than other opioids, including morphine [9]. Several studies reported that the higher BUP dose (16–32 mg/day) is safer than a lower dose of BUP (less than 16 mg/day) for treatment [10]. Generally, patients have high rates of illicit opioid use with a lower BUP dose. BUP has a ceiling effect which reduces the risk of overdose. Doses above 32 mg/day may not increase its respiratory depressant effect [11]. The regular dose of BUP for pain relief is 0.2–0.4 mg sublingually up to 3–4 times per day [6]. BUP undergoes N-demethylation to its major metabolite norbuprenorphine (NBUP) via cytochrome P4503A4 [12]. Both the metabolite and the parent drug are then metabolized to buprenorphine-glucuronide (BUP-G) and norbuprenorphine-glucuronide (NBUP-G) through glucuronidation [13]. The majority of the dose (about 50–70%) is excreted through the feces, whereas approximately 10–30% of the dose is excreted in urine, mainly as conjugated metabolites. The mean excretion ratios of BUP-G and NBUP-G in the bile after administration of 0.6 mg/kg BUP were approximately 75% and 19%, while that of BUP and NBUP were less than 1% [14].

MTD is a synthetic opioid, which is available as a racemic mixture, with R-methadone being more potent than S-methadone [15]. The use of MTD may result in overdose because it has no ceiling effect. Doses generally started at 10–30 mg/day and gradually increased every few days, up to 80–160 mg/day [5]. MTD is regularly used in pain treatment with doses...
of 5–10 mg orally 3–4 times daily [6]. After oral administration, MTD is rapidly absorbed. The measurable plasma concentration is obtained after 15 to 45 min, and peak plasma concentration is achieved after 2.5 to 4.4 h [16]. MTD is metabolized to its main metabolite 2-ethylidene-1, 5-dimethyl-3,3-diphenylpyrrolidine (EDDP) by N-demethylation [17,18]. Subsequently, it is cyclized to 2-ethylidene-5-methyl-3,3-diphenylpyrrolidine (EMDP) [18]. The structures of BUP, MTD and their metabolites are shown in Figure 1.

![Chemical structures of BUP, MTD and their metabolites.](image)

**Figure 1.** Chemical structures of BUP, MTD and their metabolites.

BUP and MTD are relatively safe alternatives to opioid drugs; however, overdoses have been a common phenomenon. Excessive usage of these drugs may result in severe physical and mental injury, or even lead to death [1]. Hence, there is a high demand of developing sensitive and selective analytical methods for monitoring of BUP, MTD and their metabolites in biological matrices.

Different biological specimens including urine [7,18–47], plasma [13,20,21,35,38,40,42–55], serum [30,56–59], blood [15,18,22,49,60–63], nails [64], oral fluid [17,31,55,65–69], hair [47,70–72], tissue [73,74] and exhaled breath condensate [75,76] have been used for the measurement of BUP, MTD and their metabolites. The preferred matrix is urine, because its sampling is non-invasive, samples can be easily collected and urine samples are usually greater in quantity in comparison with other specimens [77]. The identification and quantification of BUP, MTD and their metabolites in different matrices has been challenged due to the complexity of the biological matrix and the low concentrations of these highly potent drugs. Liquid chromatography tandem mass spectrometry (LC-MS/MS) is the preferred technique due to its high selectivity and sensitivity. Furthermore, sample pretreatment is also a crucial step to remove matrix interferences and extract the target drugs.

The search was conducted on PubMed and Google Scholar databases, using the following keywords alone or in combination: “buprenorphine”, “methadone”, “metabolite”, “biological matrix” and “analytical approach”. Inclusion criteria included: (i) articles
reviewing the determination of buprenorphine, methadone and their metabolites only in human biological samples; (ii) the type of article was original; (iii) articles published from 2017 to 2021; (iv) full-text articles. Exclusion criteria included: (i) articles were not peer-reviewed; (ii) non-English language; (iii) conference proceedings and editorials. This review is to offer an overview of the newest trends of analytical approaches published from January 2017 to December 2021 for the measurement of BUP, MTD and their metabolites in biological matrices. We divide the review into three sections. First, we present the commonly applied biological matrices. Second, we introduce the pretreatment procedures applied in recent studies to extract BUP, MTD and their metabolites from biological matrices. Finally, we review the analytical techniques reported for the monitoring of BUP, MTD and their metabolites in biological matrices. The review focuses on analytical methods based on the use of liquid chromatography tandem mass spectrometry (LC-MS/MS), since it is the most preferable technique for the analysis of BUP, MTD and their metabolites. Other methods including liquid chromatography (LC), gas chromatography (GC), electrochemical sensor, capillary electrophoresis (CE) and related techniques are also critically introduced, especially the main advantages and drawbacks of these methods.

2. Biological Matrices

Conventional biological matrices including urine, blood, plasma and serum have been used for decades for the analysis of BUP, MTD and their metabolites. Urine is the most commonly applied biological matrix likely due to the fact that the procedure is less invasive, samples can be easily collected, and sample volumes are usually larger than other matrices. However, adulteration of the urine may produce false-negative results [77]. Although the sample collection is invasive and needs medically trained staffs and requires appropriate conditions to be stable, blood (plasma, serum) is undoubtedly still widely applied in the analysis of BUP, MTD and their metabolites due to its relatively homogeneous matrix and detectable unchanged substance [78–80]. Nowadays, besides blood and urine, more and more unconventional biological specimens including nails, oral fluid (saliva), hair, tissue and exhaled breath condensate are applied as available alternatives to the traditional matrices.

Hair and nail sample collection are non-invasive, easy to perform and easy to store, transport and handle even under adverse conditions, decreasing the risk of sample degradation [81]. Preparation of hair and nail matrices requires several complex steps before the extraction procedure, including decontamination and homogenization [81]. The decontamination process of the hair and nail can remove the exogenous contaminants, dirt fragment and grease [82]. However, during the washing procedure, hair and nail damage may occur which can lead to the decomposition of some components. Additionally, the preparation of hair and nail matrices is laborious, time-consuming and increases the risks of errors.

Oral fluid consists of saliva and has been applied as an alternative matrix in the assessment of drugs levels. The sample collection of this matrix is quite easy, non-invasive and does not need trained professionals. Additionally, in comparison with urine or plasma, oral fluid testing is less influenced by endogenous interference. However, oral fluid analysis also has a variety of drawbacks. Generally, drug concentrations in oral fluid may be lower than concentrations in conventional biological matrices. Furthermore, drug concentrations of salivary can be highly dependent on the salivary pH and flow [17,83].

Other unconventional biological matrices like vitreous humor (VH) and skeletal tissue offer several advantages than traditional biological matrices. The sample collection of VH and skeletal tissue are easy and there are no interfering analytes that embarrass forensic toxicology testing in this matrix [84]. In addition, these matrices remain stable for a long time even after death [85]. A few studies have been reported in describing the determination of BUP, MTD and their metabolites in VH and skeletal tissue [39,74,85]. They concluded that VH and skeletal tissue are particularly important alternative matrices for post-mortem biochemical investigations.
Exhaled breath condensate has attracted substantial interest since the late 1990s. The important advantage of exhaled breath condensate is that breath collection is non-invasive, safe, non-destructive and can be collected “on demand” in a time as short as seconds [86,87]. Herein, breath analysis is excellent compared to conventional biological matrices making it a useful tool in detection.

3. Sample Pretreatment

A sample pretreatment before the analysis of BUP, MTD and their metabolites in biological matrices is necessary. Various sample pretreatment techniques have been reported. Simple sample pretreatment procedures like evaporation [13,72,75] and dilution [26,34,39] have been applied. Agostini et al. [26] employed a UHPLC-MS/MS technique for the analysis of BUP, NBUP, BUP-G and NBUP-G in urine samples. Urine samples were directly analyzed after dilution in water containing formic acid. This rapid and automatable method is a potential tool for routine quantification of BUP and its metabolites. Nevertheless, the most commonly employed sample pretreatment for the monitoring of BUP, MTD and their metabolites in biological matrices are liquid-liquid extraction (LLE) [18–23,40,47,49,50,52–54,56,60,61,63,65,68,69,71,74,76,77,80,88–92] and solid-phase extraction (SPE) [7,24,28,38,43–46,48,55,58,72,73,75,93–95]. The major benefits of LLE are its simplicity and high recovery in the monitoring of BUP, MTD and their metabolites in biological samples. Various solvents have been applied to extract BUP, MTD and their metabolites, including ethyl acetate [18,60], butyl chloride [59], hexanes or a mixture of solvents including methyl t-butyl ether/hexane (2:1, v:v) [52] or hexane/ethyl acetate (9:1) [72]. Nowadays, liquid microextraction techniques have been developed to minimize the organic solvent consumption, which decreases the risk of environmental pollution and reduces the analysis costs. Fernández et al. [67] described a UHPLC-MS/MS technique for the monitoring of 20 illegal drugs in oral fluid samples based on dispersive liquid–liquid microextraction (DLLME). The cloudy solution was formed when 200 µL of CHCl₃ was added. Then the mixture was put in an ultrasonic bath for 5 min and centrifuged for 5 min. After that, the extraction phase was collected and dried under nitrogen flow. Finally, the sediment was redisolved in the mobile phase and injected into the GC-MS system.

Another sample preparation method for efficient preconcentration of BUP, MTD and their metabolites is SPE. SPE has received much attention due to its simplicity, short extraction time and low solvent consumption. A number of sorbents have been employed for the extraction and detection of BUP, MTD and their metabolites, including magnetic nanoparticles (NPs) [45], molecularly imprinted polymers (MIPs) [42] and metal-organic frameworks [40]. Lamei et al. [45] utilized a magnetic nanocomposite composed of Fe₃O₄ nanoparticles/graphene oxide/deep eutectic solvent (Fe₃O₄@GO-DES) to extract MTD from urine and plasma samples. The determination was carried out using both gas chromatography-mass spectrometry (GC-MS) and gas chromatography-flame ionization detector (GC-FID) to achieve the best accuracy. With this sorbent, a high preconcentration factor (PF) of 250 was obtained. Ganjavi et al. [42] synthesized a magnetic MIP for extraction of BUP in biological fluids and tablets. Owing to its high surface area and selective recognition, a high sorption capacity (76.9 mg/g) was observed. Similarly, Mohammadi et al. [40] evaluated the efficiency of metal-organic frameworks (zeolitic imidazole framework-67) for extraction and detection of BUP in biological fluids. The zeolitic imidazole framework-67 was selected due to its high extraction recovery (95–111%) for the monitoring of BUP in biological fluids.

4. Liquid Chromatography Hyphenated Techniques

Among chromatographic techniques, LC is considered the preferred choice for the determination of BUP, MTD and their metabolites. The benefits of HPLC for detecting BUP, MTD and their metabolites in biological samples including high selectivity, sensitivity and reproducibility. In addition, compared to GC, no complicated derivatization steps are needed. Table 1 summarizes the details based on the use of LC techniques utilized
for BUP and MTD measurement. LC can be coupled with ultraviolet (UV) [40–43,54], photodiode array detector (PAD) [40], fluorescence (FL) and electrochemical (EC) [29,38] MS detection [7,13,15,18,23–28,49,50,52,56,60–62,64,65,68–73,88]. Reversed-phase columns (C18 or C8 columns) with spherical sorbent particles are popular for the determination of BUP, MTD and their metabolites. The limits of detections (LODs) of the methods are extremely low, which is due to the high sensitivity of detectors and high selectivity of the sorbents. In a study, Ganjavi et al. [43] synthesized MIPs for the selective extraction of BUP from plasma and urine by LC-UV. Due to its good selectivity and high adsorption capacity, the method exhibits excellent clean up properties. The advantages of the method included wide linear dynamic range (LDR), low limit of detection (3.0 µg/L), good precision and a high PF. In a similar work, Habibi et al. [94] applied magnetic MIP NPs for dispersive magnetic solid-phase extraction (DMSPE) of BUP in human urine samples, followed by LC-FL analysis. After MSPE, the LOD and recovery of the method achieved 0.21 µg/L and 97.4–100.3%, respectively. The method tended to be a potential and innovative sample treatment and detection method in routine drug analysis.

Table 1. LC techniques applied for the analysis of BUP, MTD and their metabolites in biological samples.

| Target Analytes | Matrices | Techniques | Extraction | Mobile Phase | LOD (LOQ or LLOQ) | Ref. |
|-----------------|----------|------------|------------|--------------|------------------|------|
| BUP, NAL, their metabolites | Urine | LC-MS/MS (Gemini-NX C18, 100 mm × 2.1 mm, 4 µm; C18 guard column, 4 mm × 2 mm) | SPE | Methanol and ammonium acetate buffer (both containing 0.1% formic acid) | BUP: 0.3 µg/L, NAL: 0.5 µg/L, NAL-G: 1 µg/L, BUP-G: 0.3 µg/L, NBUP-G: 1 µg/L | [7] |
| BUP, NAL, their metabolites | Plasma | LC-MS/MS (Thermo HILIC, 100 mm × 2.1 mm, 3.5 µm) | LLE | 60% MeCN and 40% aqueous 25m M ammonium formate (pH 3.5) | / | [13] |
| MTD, EDDP | Post-mortem samples | LC-MS/MS SFC-MS/MS (AGP, 100 mm × 2.1 mm, 5 µm; 10 mm × 2.0 mm; 5 µm) | SPE | 10 mM Ammonium acetate (pH 3.8) and isopropanol | MTD: 2.5 µg/L in LC, 0.5 µg/L in SFC | [15] |
| MTD, EDDP, EMDP | Post-mortem Matrices | LC-MS/MS (Kinetex XB-C18, 150 mm × 2.1 mm, 2.6 µm) | LLE | / | LLOQ: MTD: 0.5 µg/L, EDDP: 0.5 µg/L, EMDP: 0.5 µg/L | [18] |
| BUP, NBUP, NAL | Urine | LC-MS/MS (CORTECS Phenyl, 50 mm × 2.1 mm, 1.6 µm) | SPE | 0.05% Formic acid in water and 0.1% formic acid in acetonitrile | LLOQ: NBUP: 5 µg/L | [23] |
| MTD, BUP and other drugs | Urine | UHPLC-MS/MS (HSS T3, 100 mm × 2.1 mm, 1.8 µm) | LLE | Methanol and 5 mM ammonium acetate containing 0.025% formic acid in water | BUP: 2 µg/L, NBUP: 2 µg/L, MTD: 1 µg/L, EDDP: 0.5 µg/L | [25] |
| BUP, NBUP and their metabolites | Urine | UHPLC-MS/MS (PFP, 50 mm × 2.1 mm, 1.9 µm) | / | 95% ACN with 0.1% formic acid and 5% formic acid | BUP: 0.5 µg/L, NBUP: 1.5 µg/L, NBUP-G: 0.5 µg/L, BUP-G: 1.0 µg/L | [26] |
| 16 Drugs | Urine | LC-MS (XDB C18, 150 mm × 2.1 mm, 5 µm) | SPE | Ultra-pure water/0.1% HCOOH and MeOH/0.1% HCOOH | MTD: 5 µg/L, EDDP: 20 µg/L | [27] |
| BUP, NBUP | Urine | LC-MS/MS | / | / | BUP: 0.5 µg/L, NBUP: 0.5 µg/L | [28] |
| MTD, tramadol | Vitreous Humor | UPLC-PDA (C18, 150 mm × 3 mm) | DLLME | Phosphate buffer (pH = 2.32) and acetonitrile | MTD: 3 µg/L | [39] |
| Target Analytes | Matrices | Techniques | Extraction | Mobile Phase | LOD (LOQ or LLOQ) | Ref. |
|----------------|----------|------------|------------|--------------|------------------|-----|
| BUP Serum      | UPLC-PDA/UV (C18, 250 mm × 4.6 mm, 5 µm) | SPE | 95% Methanol and 5% deionized water containing 4 mM 1-octane sulfonic acid | 0.15 µg/L | [40] |
| BUP Plasma, urine, tablets | LC-UV (ODS-H C18, 150 mm × 4.6 mm, 5 µm) | MSPE | 0.01 M Phosphate buffer (pH 3.1) and acetonitrile | 0.6 µg/L | [42] |
| BUP Plasma, urine | LC-UV (ODS-H C18, 150 mm × 4.6 mm, 5 µm) | SPE | Acetonitrile and 0.01 M phosphate buffer with pH 3.1 | 3 µg/L | [43] |
| MTD, EDDP Dried blood spots | LC-MS/MS (Chiral-AGP, 150 mm × 4.6 mm, 5 µm) | LLE | Acetonitrile (gradient from 10 to 34%) in 0.1% formic acid (pH 6.5) | / | [49] |
| BUP Plasma | LC-MS/MS (XB-C18, 50 mm × 2.1 mm, 2.6 µm) | LLE | 0.1% Formic acid and methanol | 0.25 µg/L | [50] |
| BUP, gabapentin Serum | LC-MS/MS (Biphenyl 100Å, 50 mm × 2.1 mm, 5 µm) | LLE | 10 mM Ammonium formate and methanol containing 0.1% formic acid | BUP: 1 µg/L, NBUP: 0.3 µg/L | [56] |
| MTD Serum | LC-ECD (RP18, 50 mm × 4.6 mm, 5 µm) | LLE | 10 mM Na2HPO4, CH3CN and CH3OH | 0.5 µg/L | [59] |
| MTD, BUP and their metabolites Blood | UHPLC-MS-MS (BEH C18, 150 mm × 2.1 mm, 1.7 µm) | LLE | 0.1% Formic acid in water and 0.1% formic acid in methanol | MTD: 0.41 µg/L, EDDP: 1.41 µg/L, BUP: 0.59 µg/L, NBUP: 0.66 µg/L | [61] |
| MTD, BUP, EDDP and other opioids Whole blood | UPLC-HRMS (HSS T3, 50 mm × 2.1 mm, 1.8 µm) | LLE | 0.1% Formic acid in water and 0.1% formic acid in acetonitrile | BUP: 0.15 µg/L, NBUP: 0.1 µg/L, MTD: 0.5 µg/L, EDDP: 0.5 µg/L | [62] |
| MTD, EDDP Dried blood spots and plasma | LC-MS/MS (Eclipse XDB, 12.5 mm × 4.6 mm, 5 µm) | / | 0.1% Formic acid in water and methanol | LLOQ: MTD: 0.1 µg/L, EDDP: 0.1 µg/L, EMED: 0.1 µg/L | [63] |
| MTD, COC, methamphetamine Oral fluid | LC-MS/MS | SPME | 0.1% Ammonium formate aqueous solution | MTD: 1.5 µg/L | [66] |
| MTD, EDDP and other 15 drugs Oral fluid | LC-MS/MS (Hypersil PFP, 50 mm × 2.1 mm, 1.9 µm) | / | 0.1% Formic acid in water and 0.1% formic acid in methanol| / | [67] |
| 20 Drugs Oral fluid | UPLC-MS/MS (RP 18, 100 mm × 2.1 mm, 1.7 µm) | UADLLME | 0.1% Formic acid in water and 0.1% formic acid in acetonitrile | BUP: 1 µg/L, MTD: 0.1 µg/L, EDDP: 0.5 µg/L | [68] |
| Novel synthetic opioids, morphine and BUP Oral fluid | LC-MS/MS (EC-C18, 100 mm × 3.0 mm, 2.7 µm; 2.1 mm × 5.0 mm, 2.7 µm) | SPE | 0.05% Formic acid, 5mM ammonium formate in water and 0.1% formic acid in acetonitrile | BUP: 5 µg/L | [69] |
| 21 Drugs Oral fluid | UHPLC-MS/MS (RP 18, 100 mm × 2.1 mm, 1.7 µm) | MEPS | 0.1% Formic acid in water and 0.1% formic acid in acetonitrile | LOQs: 0.5–1 µg/L | [70] |
| 60 Drugs Hair | UHPLC-HRMS/MS (PFP, 100 mm × 2.1 mm, 2.6 µm) | DLLME | 0.1% Formic acid in water and 0.1% formic acid in acetonitrile/mehanol | BUP: 2 pg/mg, NBUP: 2 pg/mg, MTD: 0.2 µg/L, EDDP: 0.5 pg/mg | [71] |
### Table 1. Cont.

| Target Analytes | Matrices                  | Techniques                      | Extraction | Mobile Phase                        | LOD (LOQ or LLOQ)                     | Ref. |
|-----------------|---------------------------|---------------------------------|------------|-------------------------------------|---------------------------------------|------|
| MTD, EDDP, EMDP| Skeletal tissue           | LC-MS/MS (BEH C18, 50 mm × 2.1 mm, 1.7 µm) | LLE        | An aqueous buffer (pH 4) and acetonitrile | MTD: 0.1 ng/g, EDDP: 0.17 ng/g, EMDP: 0.11 ng/g | [74] |
| BUP, MTD, oxycodone, fentanyl, tramadol | Postmortem Matrices | UPLC-MS/MS                     | LLE        | /                                   | LLOQ: MTD: 0.011 µg/mL, BUP: 0.94 µg/L | [75] |
| 28 Drugs        | Exhaled breath            | LC-MS/MS (BEH phenyl, 100 mm × 2.1 mm, 1.7 µm) | LLE        | 5% Methanol in water with 4 mM ammonium formate and 5% methanol in water with 0.1% ammonia | MTD: 1.2 pg/filter, EDDP: 0.5 pg/filter, BUP: 4 pg/filter, NBUP: 10 pg/filter | [76] |
| 40 Drugs        | Breast milk               | LC-MS/MS (RP18, 125 mm × 2.0 mm, 5 µm) | LLE        | Acetonitrile and water containing 20 mM formic acid/ammonium formate buffer (pH 3.8) | MTD: 0.5 µg/L, EDDP: 0.2 µg/L | [88] |
| BUP, NBUP       | Whole blood               | LC-MS/MS                        | LLE        | 0.1% Formic acid in acetonitrile, methanol and 0.1% formic acid in water | BUP: 4.4 µg/L, NBUP: 3.4 µg/L | [96] |

In a clinical study, LC with an EC was utilized to monitor MTD in the blood samples [59]. The low LOD of 0.5 ng/mL was comparable to the LC/MS/MS method. The method was specific enough for the monitoring of serum MTD levels in cancer patients. Gomar et al. [54] proposed a LC-UV method coupled with MSPE for the monitoring of BUP and its metabolites in human plasma samples. The MSPE technique was based on a poly para-phenylenediamine modified Fe$_3$O$_4$ NPs (PpPDA/Fe$_3$O$_4$), which greatly improved the extraction efficiency (>90%) and decreased the analysis time (<20 min).

UHPLC is usually recognized as an alternative to current LC, owing to its higher separation efficiency and shorter analysis time. Mohammadi et al. [40] proposed a UHPLC method for the monitoring of BUP in biological fluids after dispersive SPE sample pretreatment with zeolitic imidazole framework-67. The instrument was equipped with a PDA and a UV detector. This method obtained a very low LOD of 0.15 µg/L and a small consumption of organic solvent (1.9 mL). Akhgari et al. [39] demonstrated a UHPLC-PDA method for the quantification of MTD and tramadol in postmortem VH samples after DLLME sample pretreatment with chloroform and methanol. The developed method exhibited a low LOD (3 µg/L) and high levels of accuracy (99.4–100%) for MTD analysis. The method was adequate for the monitoring of MTD and tramadol in forensic toxicology analysis.

Tandem mass spectrometry (MS/MS) and high-resolution mass spectrometry (HRMS) were widely applied in the identification and quantification of analytes due to their high sensitivity, which usually may achieve ultra-trace concentration levels. Mariottini et al. [7] described an automated SPE coupled with LC-MS/MS method for the quantification of BUP, naloxone (NLX) and their metabolites in urine samples. The LODs of these compounds were ranged from 0.3 to 1.0 µg/L. Chan et al. [90] reported the simultaneous monitoring of BUP and NBUP in whole blood samples by LC-MS/MS method. The LOQs of BUP and NBUP were 4.4 and 3.4 µg/L, respectively. The blood samples were extracted with a mixture of ethyl acetate and cyclohexane, then centrifuged at 6000 rpm for 10 min, injected into a Kinetex 5u C18 100A column and eluted with a mixture of acidic acetonitrile, methanol and acidic water mobile phase. The fast UHPLC separation can be utilized to monitor the multi-analyte mixtures in biological samples. Application of UHPLC-HRMS technique for the measurement of 16 opioids and derivateis, including BUP, NBUP, MTD and EDDP after LLE sample preparation with zinc sulfate, methanol and acetonitrile was...
developed by Feliu et al. [61]. The method required only 100 µL of the blood sample. Fast analysis and acquisition time (5.10 min) was achieved using a UHPLC Waters Acquity HSS T3 column (50 mm × 2.10 mm, 1.8 µm) at 50 °C with a gradient composed of water (containing 0.1% formic acid) and acetonitrile (containing 0.1% formic acid). The retention times of BUP, NBUP, MTD and EDDP were 3.48, 3.3, 3.59 and 3.53, respectively. The LODs obtained ranged from 0.1 to 0.5 µg/L. In another study, a LC-MS method was utilized for the measurement of MTD, COC and methamphetamine (MTA) in oral fluid after the microextraction technique with a nylon 6 modified wooden toothpick (N6-WT) [65]. The LOD was 0.5 µg/L for MTD. These low LODs were obtained owing to the microextraction techniques applied in the sample pretreatment and the high-sensitivity detector. However, Agostini et al. [26] proposed the use of the automatatable UHPLC-MS/MS method for the measurement of BUP and its metabolite in urine samples without any sample pretreatment. The diluted urine samples were directly analyzed by UHPLC-MS/MS. The obtained LODs of BUP and its metabolite were as low as 0.5–1.5 µg/L. The retention times of BUP and NBUP were 4.44 and 3.69, respectively. In addition, the method was applied to 30 real urine samples. The metabolic ratio calculated as NBUP/BUP gave an idea of the intake time. For example, NBUPtot/BUPtot ratio equal to 1 indicated 7–10 h after BUP intake. The combination of UHPLC and MS/MS greatly improves the specificity and separation speed. However, it also has drawbacks such as high cost and large size of the instruments. Other applications of LC-MS/MS or LC-HRMS technique for the monitoring of BUP, MTD and their metabolites in biological samples have also been listed in Table 1.

5. Gas Chromatography Hyphenated Techniques

GC methods applied for the measurement of MTD, BUP and their metabolites are summarized in Table 2. In most of the studies, GC is not as widely utilized as LC for the quantitation of BUP, MTD and their metabolites in biological matrices. As GC can only work with volatile and semi-volatile constituents, a complex derivatization step prior to GC analysis is required, resulting in an increase of the overall time required to analyze the targets. To reduce this time, Lin et al. [91] established a GC-MS method coupled with a UADLLME pretreatment procedure for the monitoring of seven recreational drugs (including MTD) in human blood samples, without derivatization. The UA-DLLME procedure was conducted by using methanol as the dispersing solvent and dichloromethane as the extraction solvent. The main advantages of this UADLLME method were the low consumption of dichloromethane (200 µL) and blood volume (200 µL), making it available for forensic cases. Lamei et al. [45] reported a pretreatment method based on MSPE for monitoring of MTD in urine and plasma samples. A new adsorbent was prepared by coating a new deep eutectic solvent onto the magnetic GO surface, which was donated as Fe₃O₄@GO-DES. The synthesized Fe₃O₄@GO-DES was used for efficient extraction of MTD. Finally, both GC-FID and GC-MS were applied to detect the MTD. The obtained LODs of the method were 0.8 µg/L for GC-FID and 0.03 µg/L for GC-MS. In addition, the high PF was 250.

Besides urine, blood and plasma samples, GC-MS analysis of MTD, BUP and their metabolites in oral fluid has also been reported. Oral fluid testing is non-invasive and less influenced by endogenous interference. Thus, it is more desirable for detecting MTD and BUP in patients. For example, Shekari et al. [89] used an ultrasound assisted DLLME (UADLLME) as a sample pretreatment method for MTD measurement in saliva. The saliva samples were extracted by sodium hydroxide and chloroform and held at ultrasonic bath before introduced into GC-MS analysis. The researchers also investigated the DLLME/GC-MS method for the detection of MTD in saliva, which required more extraction solvent and provided lower recovery in comparison with the UADLLME/GC-MS method. Ribeiro et al. [17] described the utilization of GC-MS/MS for the monitoring of MTD and EDDP in oral fluid samples. The dried saliva spots (DSS) were applied for the collection and preservation of oral fluid samples. The extraction procedure was performed using isopropanol as organic solvent, subsequently analyzed by GC-MS/MS system. With the utilization of
DSS and GC-MS/MS, the method was successfully applied in the quantification of MTD and EDDP in oral fluid samples from patients undergoing MMT. In another work, Ezoddin et al. [55] proposed an ultrasonic-assisted supramolecular model based on solidification of floating organic drop microextraction (UA-SM-SFO-ME) for the preconcentration of MTD in plasma and saliva samples before GC-MS analysis. A mixture of 1-Dodecanol and THF were selected as supramolecular solvents for the microextraction of MTD, which may be an appropriate alternative to organic solvents owing to its low toxicity. Moreover, the major advantage of this method was the application of ultrasonication, which provided fast extraction, high extraction recovery and low detection limit.

Table 2. GC techniques applied for the analysis of BUP, MTD and their metabolites in biological samples.

| Target Analytes | Matrices | Techniques | Extraction | LOD (LOQ or LLOQ) | Ref. |
|-----------------|----------|------------|------------|-------------------|-----|
| MTD, EDDP       | Oral fluid | GC-MS/MS (30 m × 0.25 mm, 0.25 µm) | LLE | MTD: 5 µg/L EDDP: 5 µg/L | [17] |
| MTD, TRM        | Urine    | GC-FID (HP-5, 30 m × 0.25 mm, 0.25 µm) | LLME | MTD: 2.4 µg/L | [19] |
| MTD             | Urine, plasma, saliva | GC-FID/MS (DB 5-ms, 30 m × 0.25 mm, 0.25 µm) | DLLME | GC-FID: Urine: 2.7 µg/L Plasma, saliva: 9.5 µg/L GC-MS: Urine: 0.06 µg/L Plasma, saliva: 0.2 µg/L | [20] |
| MTD             | Plasma, urine, saliva | GC-FID (HP-5, 30 m × 0.32 mm, 0.25 µm) | / | Urine: 0.5 µg/L, Plasma: 0.7 µg/L Saliva: 1.5 µg/L | [21] |
| MTD, TRM        | Urine, plasma, saliva | GC-FID (HP-5, 30 m × 0.25 mm, 0.25 µm) | SPE | Urine: MTD: 0.45 µg/L MTD: 2.5 µg/L MTD: 0.8 µg/L | [44] |
| MTD             | Urine, plasma | GC-FID/MS (HP-5, 30 m × 0.25 mm, 0.25 µm) | MSPE | GC-FID: MTD: 0.8 µg/L GC-MS: MTD: 0.03 µg/L | [45] |
| MTD, COD        | Plasma    | GC-FID (BP-5, 30 m × 0.25 mm, 0.25 µm) | LLE | MTD: 15 µg/L | [48] |
| MTD             | Plasma and saliva | GC-MS (HP-5, 30 m × 0.32 mm, 0.25 µm) | UA-SM-SFO-ME | Plasma: 1.2 µg/L Saliva: 0.7 µg/L | [55] |
| MTD             | Nail      | GC-MS (VF-5ms, 30 m × 0.32 mm, 0.25 µm) | LLE and SPE | MTD: 3.3 ng/mg EDDP: 6.0 ng/mg EMDP: 6.0 ng/mg | [64] |
| MTD, EDDP       | Hair      | GC-MS/MS (Capillary Column, 30 m × 0.25 mm, 0.25 µm) | MEPS | LLOQ: MTD: 0.01 ng/mg EDDP: 0.01 ng/mg | [71] |
| MTD, EDDP, 8 new psychoactive substances (NPS) | Hair | GC-MS (DB-5, 30 m × 0.25 mm, 0.25 µm) | LLE | MTD: 0.2 ng/mg EDDP: 0.05 ng/mg | [72] |
| MTD             | Urine     | GC-MS (HP-5MS, 30 m × 0.25 mm, 0.25 µm) | UALLE | 2.1 µg/L | [88] |
| MTD             | Saliva    | GC-MS (HP-5MS, 30 m × 0.25 mm, 0.25 µm) | UADLLME | 50 µg/L | [89] |
| 7 recreational drugs | Whole blood | GC-MS (HP-5MS, 30 m × 0.25 mm, 0.25 µm) | | MTD: 10 µg/L | [91] |
6. Other Techniques

Besides the analytical approaches based on LC and GC, other analytical techniques developed for the determination of MTD, BUP and their metabolites have also been reported, including capillary electrophoresis (CE) [46,76], electrochemical sensor [29–38,53,57,58,63], enzyme immunoassay [22], as shown in Table 3. Among these analytical approaches, electrochemical method is the most popular one due to its high sensitivity, low cost and fast response time. The citrate stabilized magnetic nanocrystals (CS-MNCs) were coated onto the surface of the carbon paste electrode (CPE) by the Farmany’s group [95]. The synthesized CS-MNCs/CPE was applied for the quantification of BUP in human plasma and urine samples. The sensor obtained a LOD of 4.3 nM. The advantages of the method were high sensitivity, simplicity, speed and no sample pretreatment or separation procedure was required. Similarly, Alizadeh et al. [34] described a MIP and multiwalled carbon nanotubes (MWCNT) modified CPE for monitoring of BUP in human urine samples without the need for pretreatment. The combination of MWCNT and MIP significantly increased the sensitivity and selectivity of the CPE. Under optimum conditions, the sensor achieved a LOD of 0.6 nM. In addition, the sensor has the potential for determination of other semi structure drugs.

Table 3. Other techniques applied for the analysis of BUP, MTD and their metabolites in biological samples.

| Analytical Techniques | Target Analytes | Matrices | Sample Pretreatment | LOD (LOQ or LLOQ) | Ref. |
|-----------------------|----------------|----------|--------------------|-------------------|-----|
| Enzyme immunoassay (ELISA) | MTD | Serum | Alkaline extraction with ethyl acetate | 0.18 µg/L | [21] |
| Electrochemical sensor | BUP | Urine | Dilution with PBS | 28 nM | [29] |
| Electrochemical sensor | MTD | Blood serum, urine | Deproteinization with methanol | 14 nM | [30] |
| Electrochemical sensor | MTD, morphine | Blood, urine, saliva | Dilution with PBS | MTD: 5.6 nM | [31] |
| Electrochemical sensor | MTD, morphine | Urine | Dilution with buffer | MTD: 3 nM | [33] |
| Electrochemical sensor | BUP | Urine | Dilution with britton buffer | 0.6 nM | [34] |
| Electrochemical sensor | MTD | Serum, urine | Deproteinization with methanol | 14 nM | [35] |
| Electrochemical sensor | MTD | Urine | Direct immersion-solid phase microextraction | 0.2 µg/L | [37] |
| Electrochemical sensor | MTD | Blood serum, urine | Deproteinization with trichloroacetic acid | 0.03 µM | [38] |
| Capillary electrophoresis | MTD, TRM | Urine, plasma | Dilution with water | MTD: 1.5 µg/L | [46] |
| Capillary electrophoresis | MTD, EDDP | Plasma | LLE with dichloromethane | LOQ: MTD: 25 µg/L EDDP: 2.5 µg/L | [53] |
| Electrochemical sensor | MTD | Blood | Deproteinization with 0.5 M sulfuric acid | 0.12 µM | [57] |
| Surface-enhanced Raman spectroscopy (SERS) | BUP | Saliva | Liquid extraction with dichloromethane | / | [92] |
Table 3. Cont.

| Analytical Techniques | Target Analytes | Matrices                  | Sample Pretreatment                    | LOD (LOQ or LLOQ)         | Ref. |
|-----------------------|-----------------|---------------------------|----------------------------------------|---------------------------|------|
| Capillary electrophoresis | MTD             | Exhaled breath Condensate, serum and urine | LLE with acetonitrile, LLOQ: 0.15 µg/mL | [76]                     |      |
| Electrochemical sensor | BUP             | Serum, urine              | Deproteinization with methanol          | 4.3 nM                    | [95] |
| Capillary electrophoresis | 46 drugs       | Whole blood               | SPE with an Oasis HLB column            | MTD: 30 µg/L, BUP: 30 µg/L | [96] |

CE and related techniques have also been effective approaches for the measurement of MTD, BUP and their metabolites due to their cost-effectiveness, automation, simplicity and less sample consumption. For example, Naghdi et al. [46] reported the use of a maltodextrin modified CE for the chiral analysis of MTD and tramadol (TRA) in tablet, urine and plasma samples. Under optimal extraction conditions, the method achieved LODs of 2 µg/mL for TRA and 1.5 µg/L for MTD. Later, Cui et al. [96] employed the CE method in combination with PAD detection for determining 46 drugs of abuse, including MTD and BUP in whole blood samples. The obtained LODs were both 30 µg/L for MTD and BUP. Finally, the method was utilized to detect real blood samples in forensic investigation. These data demonstrated that the lack of sensitivity of CE-based techniques is a main contributing factor to its limited application.

An interesting identification method was developed by Farquharson et al. [96], who described a rapid quantitation method based on surface-enhanced Raman spectroscopy (SERS) for BUP and opioids detection in saliva. A simple liquid extraction was carried out to extract the BUP from saliva. The analysis was in good agreement with the urinalysis result and most importantly, the analysis time was only 25 min. We also notice that there is a method based on enzyme immunoassay by Forouzesh’s group [22]. This is the study performed to compare two methods, ELISA and GC-MS, for measuring MTD levels. Both methods were acceptable. Nevertheless, in GC-MS the analysis range was from 30 ng–10 µg, while in ELISA the linearity was much lower, from 1.2 ng–100 ng. In general, GC-MS is preferable to ELISA due to its high sensitivity; however, ELISA can detect a large number of samples in a short time with rapid speed.

7. Conclusions

The monitoring of BUP, MTD and their metabolites in various biological specimens has been a challenging task in clinical and forensic toxicology. Unconventional biological specimens are emerging as available alternatives because they are non-invasive, easy to perform and non-destructive, while ensuring accuracy and sensitivity at the same time. Owing to the complexity of matrices, analytical procedures usually consist of sample pretreatment steps and highly sensitive instrumentation analysis. Simple LLE or SPE, especially the microextraction techniques, are commonly applied to minimize matrix interferences and maximize the target concentrations. Chromatographic techniques including LC, GC or the combination of HRMS or MS with LC or GC are applied to obtain ultra-trace concentration levels. The approaches based on LC-MS/MS are the preferable techniques for the quantitation of BUP, MTD and their metabolites in biological samples. Moreover, other methodologies are also reported by researchers, including electrochemical methods and CE-based techniques. Taking into account the serious abuse of BUP and MTD, the measurement of these compounds and their metabolites in biological matrices are worth further exploration.
Author Contributions: Writing—original draft preparation, X.S. and C.C.; writing—review and editing, B.Y. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Hangzhou Medical and Health Science and Technology Project (Grant No. A20220302) and Hangzhou Foundation for Development of Science and Technology (Grant No. 20181228Y28).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing is not applicable to the paper; all supporting data are included within the main article.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

OUD  Opioid use disorder
FDA  Food and Drug Administration
BUP  Buprenorphine
MTD  Methadone
NBUP  Norbuprenorphine
BUP-G  Buprenorphine-glucuronide
NBUP-G  Norbuprenorphine-glucuronide
EDDP  2-Ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine
EMDP  2-Ethylidene-3-methyl-3,3-diphenylpyrrolidine
LC-MS/MS  Liquid chromatography tandem mass spectrometry
LC  Liquid chromatography
GC  Gas chromatography
CE  Capillary electrophoresis
VH  Vitreous humor
UHPLC-MS/MS  Ultra-high-performance liquid chromatography-tandem mass spectrometry
LLE  Liquid-liquid extraction
SPE  Solid-phase extraction
DLLME  Dispersive liquid-liquid microextraction
GC-MS  Gas chromatography-mass spectrometry
NPs  Nanoparticles
MIPs  Molecularly imprinted polymers
Fe$_3$O$_4$@GO-DES  Fe$_3$O$_4$ nanoparticles/graphene oxide/deep eutectic solvent
GC-FID  Gas chromatography-flame ionization detector
PF  Preconcentration factor
UV  Ultraviolet
PAD  Photodiode array detector
FL  Fluorescence
EC  Electrochemical
LDR  Linear dynamic range
LOD  Limit of detection
DMSPE  Dispersive magnetic solid-phase extraction
LOQ  Limit of quantification
LLOQ  Lower limit of quantification
COC  Cocaine
MMT  Methadone maintenance treatment
PpPDA/Fe$_3$O$_4$  Poly para-phenylenediamine modified Fe$_3$O$_4$ NPs
MS/MS  Tandem mass spectrometry
HRMS  High-resolution mass spectrometry
References

1. Ahmed, S.R.; Chand, R.; Kumar, S.; Mittal, N.; Srinivasan, S.; Rajabzadeh, A.R. Recent biosensing advances in the rapid detection of illicit drugs. TrAC Trend Anal. Chem. 2020, 131, 116006. [CrossRef]

2. Dunn, K.E.; Finan, P.H.; Andrew Tompkins, D.; Strain, E.C. Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients. Addict. Behav. 2018, 76, 8–14. [CrossRef] [PubMed]

3. Strang, J.; Volkow, N.D.; Degenhardt, L.; Hickman, M.; Johnson, K.; Koob, G.F.; Marshall, B.D.L.; Walsh, S.L. Opioid use disorder. Nat. Rev. Dis. Primers 2020, 6, 4. [CrossRef] [PubMed]

4. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211–1259. [CrossRef]

5. Blanco, C.; Volkow, N.D. Management of opioid use disorder in the USA: Present status and future directions. Lancet 2019, 393, 1760–1772. [CrossRef]

6. Strand, M.C.; Vindenes, V.; Gjerde, H.; Merland, J.G.; Ramaekers, J.G. A clinical trial on the acute effects of methadone and buprenorphine on actual driving and cognitive function of healthy volunteers. Br. J. Clin. Pharmacol. 2018, 85, 442–453. [CrossRef]

7. Mariotti, C.; Gergov, M.; Ojanperä, I. Determination of buprenorphine, norbuprenorphine, naloxone, and their glucuronides in urine by liquid chromatography-tandem mass spectrometry. Drug Test. Anal. 2021, 13, 1658–1667. [CrossRef] [PubMed]

8. Papoutsis, I.I.; Nikolaou, P.D.; Athanaselis, S.A.; Pistos, C.M.; Spiliopoulou, C.A.; Maravelias, C.P. Development and validation of a highly sensitive GC/MS method for the determination of buprenorphine and nor-buprenorphine in blood. J. Pharm. Biomed. Anal. 2011, 54, 588–591. [CrossRef] [PubMed]

9. Rodriguez-Rosas, M.E.; Lofwall, M.R.; Strain, E.C.; Siluk, D.; Wainer, I.W. Simultaneous determination of buprenorphine, norbuprenorphine and the enantiomers of methadone and its metabolite (EDDP) in human plasma by liquid chromatography/mass spectrometry. J. Chromatogr. B 2007, 850, 538–543. [CrossRef] [PubMed]

10. Ayman Fareed MD, S.V.M.J. Effect of buprenorphine dose on treatment outcome. J. Addict. Dis. 2012, 31, 8–18. [CrossRef]

11. Seldén, T.; Ahlner, J.; Druid, H.; Kronsstrand, R. Toxicological and pathological findings in a series of buprenorphine related deaths. Possible risk factors for fatal outcome. Forensic Sci. Int. 2012, 220, 284–290. [CrossRef] [PubMed]

12. Tzatzarakis, M.N.; Vakonaki, E.; Kovatsi, L.; Belivanis, S.; Mantsi, M.; Alegakis, A.; Tsatsakis, A.M. Determination of buprenorphine, norbuprenorphine and naloxone in fingernail clippings and urine of patients under opioid substitution therapy. J. Anal. Toxicol. 2015, 39, 313–320. [CrossRef] [PubMed]
Molecules 2022, 27, 5211

18. Nowak, K.; Szpot, P.; Jurek, T.; Zawadzki, M. Quantification of methadone and its metabolites: EDDP and EMDP determined in autopsy cases using LC-MS/MS. *J. Forensic Sci.* 2021, 66, 1003–1012. [CrossRef]

19. Ahmar, H.; Nejati-Yazdinejad, M.; Najafi, M.; Hasheminasab, K.S. Switchable hydrophilicity solvent-based homogenous liquid–liquid microextraction (SHS-LLME) combined with GC-FID for the quantification of methadone and tramadol. *Chromatographia* 2018, 81, 1063–1070. [CrossRef]

20. Jafarinejad, M.; Ezoddin, M.; Lamei, N.; Abdi, K.; Babhadi Ashar, N.; Pirooznia, N.; Akhgari, M. Effervescent tablet-assisted demulsified dispersive liquid–liquid microextraction based on solidification of floating organic droplet for determination of methadone in water and biological samples prior to GC-flame ionization and GC-MS. *J. Sep. Sci.* 2020, 43, 3266–3274. [CrossRef]

21. Nedaei, M.; Abdi, K.; Ghorbani, S.A.; Pirooznia, N. Ultrasonic-air-assisted solidification of settled organic drop microextraction using terpene-based deep eutectic solvents for the effectual enrichment of methadone in biological samples. *Chromatographia* 2020, 83, 1413–1421. [CrossRef]

22. Forouzesh, M.; Valipour, R.; Shekari, A.; Barzegar, A.; Setareh, M. Comparison of methadone level measurement by enzyme immunoassay with gas chromatography-mass spectrometry. *J. Adv. Pharm. Educ. Res.* 2019, 9, 105–108.

23. Muñoz-Muñoz, A.C.; Pekol, T.; Awad, A.; Hackett, P.; Sullivan, L.; Rodrigues, A.; Andrade, L. Norbuprenorphine interferences in urine drug testing LC–MS/MS confirmation methods from quetiapine metabolites. *J. Anal. Toxicol.* 2021, bkb113. [CrossRef] [PubMed]

24. Da, C.K.; Rodrigues, L.C.; Huestis, M.A.; Costa, J.L. Miniaturized extraction method for analysis of synthetic opioids in urine by microextraction with packed sorbent and liquid chromatography-tandem mass spectrometry. *J. Chromatogr. A* 2020, 1624, 461241.

25. Dahlin, J.L.; Palte, M.J.; LaMacchia, J.; Petrides, A.K. A rapid dilute-and-shoot UPLC-MS/MS assay to simultaneously measure 37 drugs and related metabolites in human urine for use in clinical pain management. *J. Appl. Lab. Med.* 2019, 3, 974–992. [CrossRef]

26. Agostini, M.; Renzoni, C.; Pierini, E.; Piergiovanni, M.; Termopoli, V.; Famigli, G.; Cappiello, A. Rapid, hydrolysis-free, dilute-and-shoot method for the determination of buprenorphine, norbuprenorphine and their glucuronides in urine samples using UHPLC-MS/MS. *J. Pharm. Biomed. Anal.* 2019, 166, 236–243. [CrossRef]

27. Musile, G.; Cenci, L.; Piletska, E.; Gottardo, R.; Bossi, A.M.; Bortolotti, F. Development of an in-house mixed-mode solid-phase extraction for the determination of 16 basic drugs in urine by High Performance Liquid Chromatography-Ion Trap Mass Spectrometry. *J. Chromatogr. A* 2018, 1560, 10–18. [CrossRef]

28. Suzuki, J.; Zinser, J.; Issa, M.; Rodriguez, C. Quantitative testing of buprenorphine and norbuprenorphine to identify urine sample spiking during office-based opioid treatment. *Subst. Abus.* 2017, 38, 504–507. [CrossRef]

29. Hatefi-Mehrjerdi, A.; Boldaji, R.; Yaftian, M.R.; Shayani-Jam, H. Anion-doped overoxidized polypyrrole/multiwalled carbon nanotubes modified glassy carbon electrode as a new electrochemical sensing platform for buprenorphine opioid drug. *Iran. J. Anal. Chem.* 2021, 8, 56–64.

30. Khorablou, Z.; Shahdost-Fard, F.; Razmi, H. Flexible and highly sensitive methadone sensor based on gold nanoparticles/polythiophene modified carbon cloth platform. *Sens. Actuators B* 2021, 344, 130284. [CrossRef]

31. Akbari, S.; Jahani, S.; Foroughi, M.M.; Nadiki, H.H. Simultaneous determination of methadone and morphine at a modified electrode with 3D b-MnO2 nanoflowers: Application for pharmaceutical sample analysis. *RSC Adv.* 2020, 10, 38532–38545. [CrossRef] [PubMed]

32. Shaabani, N.; Chan, N.W.C.; Lee, W.E.; Jemere, A.B. Electrochemical determination of naloxone using molecularly imprinted poly[para-phenylenediamine] sensor. *J. Electrochem. Soc.* 2020, 167, 137508. [CrossRef]

33. Yousefi, N.; Irandoust, M.; Haghighi, M. New and sensitive magnetic carbon paste electrode for voltammetry determination of morphine and morphadine. *J. Iran. Chem. Soc.* 2017, 14, 2909–2922. [CrossRef]

34. Alizadeh, T.; Atashi, F.; Akhoundian, M.; Ganjali, M.R. Highly selective extraction and voltammetric determination of the opioid drug buprenorphine via a carbon paste electrode impregnated with nano-sized molecularly imprinted polymer. *Microchim. Acta* 2019, 186, 654. [CrossRef]

35. Karim Nezhad Ghasem, K.Z. Voltammetric Determination of methadone at stacked cysteic acid film and gold nanoparticles composite modified glassy carbon electrode. *Anal. Bioanal. Electrochem.* 2017, 9, 689–703.

36. Hosseini, M.; Pur, M.; Norouzi, P.; Moghhadam, M.R.; Ganjali, M.R. An enhanced electrochemiluminescence sensor modified with a Ru(bpy)32+ /Yb2O3 nanoparticle/nafion composite for the analysis of methadone samples. *Mater. Sci. Eng. C* 2017, 76, 483–489. [CrossRef]

37. Mohammadiazar, S.; Hasanli, F.; Maham, M.; Payami Samarin, S. Solid-phase microextraction of methadone in urine samples by electrochemically co-deposited sol-gel/Cu nanocomposite fiber. *Biomed. Chromatogr.* 2017, 31, e3926. [CrossRef]

38. Rezaei, B.; Tajaddodi, A.; Ensafi, A.A. An innovative highly-sensitive sensor based on carbon quantum dots and multilwall carbon nanotubes for electrochemical sensing and determination of methadone hydrochloride in real samples. *Anal. Methods* 2020, 12, 5210–5218. [CrossRef]

39. Akhgari, M.; Sani, N.M.; Mousavi, Z. Research Paper: Determination of methadone and tramadol in vitreous humor specimens using dispersive liquid liquid microextraction and ultra high performance liquid chromatography. *Int. J. Med. Toxicol. Forensic Med.* 2021, 11, 31530. [CrossRef]

40. Mohammadi, F.; Shabani, A.M.H.; Dadfarnia, S.; Ansari, M.; Asgharinezhad, A.A. Dispersive solid-phase extraction of buprenorphine from biological fluids using metal-organic frameworks and its determination by ultra-performance liquid chromatography. *J. Sep. Sci.* 2020, 43, 3045–3052. [CrossRef]
41. Abbasi, S.; Haeri, S.A.; Sajjadifar, S. Bio-dispersive liquid liquid microextraction based on nano rhamnolipid aggregates combined with molecularly-imprinted-solid phase extraction for selective determination of paracetamol in human urine samples followed by HPLC. *Microchim. Acta.* 2020, 187, 265. [CrossRef] [PubMed]

42. Ganjavi, F.; Ansari, M.; Kazemipour, M.; Zeidabadinejad, L. Computational design, synthesis and utilization of a magnetic molecularly imprinted polymer on graphene oxide nanosheets for highly selective extraction and determination of buprenorphine in biological fluids and tablets. *Anal. Methods* 2018, 10, 5214–5226. [CrossRef]

43. Ganjavi, F.; Ansari, M.; Kazemipour, M.; Zeidabadinejad, L. Computer-aided design and synthesis of a highly selective molecularly imprinted polymer for the extraction and determination of buprenorphine in biological fluids. *J. Sep. Sci.* 2017, 40, 3175–3182. [CrossRef]

44. Adlinasab, L.; Shahdousti, P.; Ahmar, H. Layered double hydroxide intercalated with tyrosine for ultrasonic-assisted microextraction of tramadol and methadone from biological samples followed by GC/MS analysis. *Microchim. Acta.* 2020, 187, 265. [CrossRef] [PubMed]

45. Lamei, N.; Ezoddin, M.; Ardestani, M.S.; Abdi, K. Dispersion of magnetic graphene oxide nanoparticles coated with a deep eutectic solvent using ultrasound assistance for preconcentration of methadone in biological and water samples followed by GC–FID and GC–MS. *Anal. Bioanal. Chem.* 2017, 409, 6113–6121. [CrossRef] [PubMed]

46. Naghdi, E.; Fakhari, A.R. Simultaneous chiral separation of tramadol and methadone in tablets, human urine, and plasma by capillary electrophoresis using maltodextrin as the chiral selector. *Chirality* 2018, 30, 1161–1168. [CrossRef]

47. Abedi, H. Solid-phase microextraction of methadone by using a chitosan nanocomposite incorporated with Polyoxomolinebdate nanocluster/Graphene oxide. *J. Sep. Sci.* 2021, 44, 1969–1977. [CrossRef]

48. Jamil, L. Optimization of New Sample preparation technique for the determination of methadone and codeine in plasma sample by GC-FID. *J. Braz. Chem. Soc.* 2020, 31, 580–588. [CrossRef]

49. Metzger, I.F.; Thomas, A.E.; Evrard, C.A.; Jones, D.R.; Masters, A.R.; Haas, D.M.; Quinney, S.K. Stereoselective analysis of methadone and EDPP in laboring women and neonates in plasma and dried blood spots and association with neonatal abstinence syndrome. *Ann. J. Perinat.* 2021, 38, 968–975. [CrossRef]

50. Tikhomirov, M.; Pozniak, B.; Śniegocki, T. High-performance liquid chromatography-tandem mass spectrometry for buprenorphine evaluation in plasma—Application to pharmacokinetic studies in rabbits. *Molecules* 2021, 26, 437. [CrossRef]

51. Kongstad, K.T.; Papathanasiou, T; Springborg, A.D.; Lund, T.M.; Werner, M.U.; Staerk, D. Simultaneous quantification of high-dose naloxone and naloxone-3-β-d-glucuronide in human plasma by UHPLC–MS/MS. *Bioanalysis* 2019, 11, 165–173. [CrossRef] [PubMed]

52. Liu, Y.; Li, X.; Xu, A.; Nasser, A.F.; Heidbreder, C. Simultaneous determination of buprenorphine, norbuprenorphine and naloxone in human plasma by liquid chromatography/tandem mass spectrometry. *J. Pharm. Biomed. Anal.* 2016, 120, 140–152. [CrossRef]

53. Theurillat, R.; Sandbaumhuter, F.A.; Gittel, C.; Larenza, M.M.; Braun, C.; Thormann, W. Enantioselective capillary electrophoresis for pharmacokinetic analysis of methadone and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine in equines anesthetized with ketamine and isoflurane. *Electrophoresis* 2019, 40, 1959–1965. [CrossRef] [PubMed]

54. Gomar, F.; Afkhami, A.; Madrakian, T. Highly sensitive simultaneous quantification of buprenorphine and norbuprenorphine in human plasma by magnetic solid-phase extraction based on PpPDA/Fe₃O₄ nanocomposite and high-performance liquid chromatography. *J. Iran. Chem. Soc.* 2018, 15, 575–585. [CrossRef]

55. Ezoddin, M.; Adlinasab, L.; Kaveh, A.A.; Karimi, M.A. Ultrasonically formation of supramolecular based ultrasound energy assisted solidification of floating organic drop microextraction for preconcentration of methadone in human plasma and saliva samples prior to gas chromatography—Mass spectrometry. *Ultrason. Sonochem.* 2019, 50, 182–187. [CrossRef] [PubMed]

56. Phillips, S.J.; Oliveto, A.; Mancino, M.J.; Hendrickson, H.P. Development and validation of a rapid liquid chromatography/tandem mass spectrometry method to quantify gabapentin and buprenorphine in human urine. *Rapid Commun. Mass Spectrom.* 2021, 35, 9104. [CrossRef] [PubMed]

57. Baghayeri, M.; Nabavi, S.; Hasheminejad, E.; Ebrahimi, V. Introducing an electrochemical sensor based on two layers of Ag nanoparticles decorated graphene for rapid determination of methadone in human blood serum. *Top. Catal.* 2022, 65, 623–632. [CrossRef]

58. Jahanbakhshi, M. In situ synthesis of rhodium nanoparticles—Mesoporous carbon hybrid via a novel and facile nanocasting method for simultaneous determination of morphine and buprenorphine. *Mater. Sci. Eng. C* 2019, 97, 479–485. [CrossRef]

59. Kokubun, H.; Takigawa, C.; Miyano, K.; Uezono, Y. A novel method for determination of methadone in the serum by high-performance liquid chromatography with electrochemical detection. *Biol. Pharm. Bull.* 2018, 41, 649–651. [CrossRef]

60. Orfanidis, A.; Gika, H.G.; Theodoridis, G.; Mastrogianni, O.; Raikos, N. A UHPLC-MS-MS method for the determination of 84 drugs of abuse and pharmaceuticals in blood. *J. Anal. Toxicol.* 2021, 45, 28–43. [CrossRef]

61. Feliu, C.; Konecki, C.; Binet, L.; Vautier, D.; Haudecoeur, C.; Oget, O.; Djerada, Z. Quantification of methadone, buprenorphine, naloxone, opioids, and their derivates in whole blood by liquid chromatography-high-resolution mass spectrometry: Analysis of their involvement in fatal forensic cases. *J. Chromatogr. B* 2020, 1152, 122226. [CrossRef] [PubMed]

62. Davari, B.; Kotecha, N.; Clavijo, C.F.; Thomas, J.J.; Rzasa-Lynn, R.; Galinkin, J.L.; Christians, U.; Sempio, C. A sensitive LC-MS/MS assay for the quantification of methadone and its metabolites in dried blood spots: Comparison with plasma. *Ther. Drug Monit.* 2020, 42, 118–128. [CrossRef] [PubMed]
63. Yahyapour, M.; Ranjbar, M.; Mohadesi, A.; Rejaie-negad, M. Determination of buprenorphine (BUP) with molecularly imprinted polymer Zn/La\textsuperscript{3+} metal organic framework on modified glassy carbon electrode (GCE). *Electroanalysis* **2022**, *34*, 1012–1020. [CrossRef]

64. Magalhaes, T.P.; Cravo, S.; Silva, D.; Dinis-Oliveira, R.J.; Afonso, C.; Lourdes, B.M.; Carmo, H. Quantification of Methadone and Main Metabolites in Nails. *J. Anal. Toxicol.* **2018**, *42*, 192–206. [CrossRef] [PubMed]

65. Millán-Santiago, J.; García-Valverde, M.T.; Lucena, R.; Cárdenas, S. Polyamide-coated wooden tips coupled to direct infusion mass spectrometry, a high throughput approach for the determination of methadone, cocaine and methamphetamine in oral fluid. *Microchem.* **2021**, 162, 105843. [CrossRef]

66. Bassotti, E.; Merone, G.M.; D Urso, A.; Savini, F.; Locatelli, M.; Tartaglia, A.; de Grazia, U. A new LC-MS/MS confirmation method for the determination of 17 drugs of abuse in oral fluid and its application to real samples. *Forensic Sci. Int.* **2020**, *312*, 110330. [CrossRef]

67. Fernández, P.; Regenjo, M.; Ares, A.; Fernández, A.M.; Lorenzo, R.A.; Carro, A.M. Simultaneous determination of 20 drugs of abuse in oral fluid using ultrasound-assisted dispersive liquid–liquid microextraction. *Anal. Bioanal. Chem.* **2019**, *411*, 193–203. [CrossRef]

68. Truver, M.T.; Swortwood, M.J. Quantitative analysis of novel synthetic opioids, morphine and buprenorphine in oral fluid by LC–MS–MS. *J. Anal. Toxicol.* **2018**, *42*, 554–561. [CrossRef]

69. Ares, A.M.; Fernández, P.; Regenjo, M.; Fernández, A.M.; Carro, A.M.; Lorenzo, R.A. A fast bioanalytical method based on microextraction by packed sorbent and UPLC–MS/MS for determining new psychoactive substances in oral fluid. *Talanta* **2017**, *174*, 454–461. [CrossRef]

70. Vincenti, F.; Montesano, C.; Cellucci, L.; Gregori, A.; Fantin, F.; Compagnone, D.; Sergi, M. Combination of pressurized liquid extraction with dispersive liquid micro extraction for the determination of sixty drugs of abuse in hair. *J. Chromatogr. A* **2019**, *1605*, 860348. [CrossRef]

71. Rosado, T.; Gallardo, E.; Veira, D.N.; Barroso, M. Microextraction by packed sorbent as a novel strategy for sample clean-up in the determination of methadone and EDDP in hair. *J. Anal. Toxicol.* **2020**, *44*, 840–850. [CrossRef] [PubMed]

72. Anzillotti, L.; Calo, L.; Giacalone, M.; Banchini, A.; Cecchi, R. Determination of methadone and eight new psychoactive substances in hair samples by gas chromatography/mass spectrometry. *J. Forensic Sci. Med. Sci.* **2018**, *4*, 184. [CrossRef]

73. Vandenbosch, M.; Somers, T.; Cuypers, E. Distribution of methadone and metabolites in skeletal tissue. *J. Anal. Toxicol.* **2018**, *42*, 400–408. [CrossRef] [PubMed]

74. Havig, S.M.; Vindenes, V.; Øiestad, A.; Rogde, S.; Thaulow, C.H. Methadone, buprenorphine, oxycodeone, fentanyl, and tramadol in multiple postmortem matrices. *J. Anal. Toxicol.* **2022**, *46*, 600–610. [CrossRef] [PubMed]

75. Üllah, S.; Sandqvist, S.; Beck, O. A liquid chromatography and tandem mass spectrometry method to determine 28 non-volatile drugs of abuse in exhaled breath. *J. Pharm. Biomed. Anal.* **2018**, *148*, 251–258. [CrossRef]

76. Hamidi, S.; Khoubnasabjafari, M.; Ansarin, K.; Jouyban-Gharamaleki, V.; Jouyban, A. Chiral separation of methadone in exhaled breath condensate using capillary electrophoresis. *J. Chromatogr. A* **2017**, *1605*, 452–460. [CrossRef]

77. Pérez-Alcaraz, A.; Borrull, P.; Calull, M.; Aguilar, C. Cathinones in urine samples: A review of recent advances for their determination by chromatographic and related techniques. *TrAC Trends Anal. Chem.* **2021**, *143*, 116347. [CrossRef]

78. Rivier, L. Techniques for analytical testing of unconventional samples. *Best Pract. Res. Clin. Endocrinol. Metab.* **2000**, *14*, 147–165. [CrossRef]

79. Langel, K.; Gjerde, H.; Favretto, D.; Lillsunde, P.; Øiestad, E.L.; Ferrara, S.D.; Verstraete, A.G. Comparison of drug concentrations between whole blood and oral fluid. *Drug Test. Anal.* **2014**, *6*, 461–471. [CrossRef]

80. Silveira, G.D.O.; Pego, A.M.F.; Pereira E Silva, J.; Yonamine, M. Green sample preparations for the bioanalysis of drugs of abuse in exhaled breath. *J. Anal. Toxicol.* **2019**, *43*, 295–312. [CrossRef] [PubMed]

81. Dutkiewicz, E.P.; Urban, P.L. Quantitative mass spectrometry of unconventional human biological matrices. *Philos. Trans. R. Soc. A* **2016**, *374*, 20150380. [CrossRef] [PubMed]

82. Boubma, V.; Zivaou, K.; Vougiouklakis, T. Hair as a Biological Indicator of Drug Use, Drug Abuse or Chronic Exposure to Environmental Toxicants. *Int. J. Toxicol.* **2006**, *25*, 143–163. [CrossRef] [PubMed]

83. Lomonaco, T.; Ghimenti, S.; Biagini, D.; Bramanti, A.M.; Fenzi, L.; Banchini, A.; Fantin, F.; Bottinelli, C.; Fanton, L.; Guitton, J. Vitreous humor analysis for the detection of xenobiotics in forensic toxicology: A review. *Toxicology* **2018**, *42*, 184. [CrossRef] [PubMed]

84. Giordano, G.; Biehler-Gomez, L.; Seneci, P.; Cattaneo, C.; Di Candia, D. Detecting drugs in dry bone: A pilot study of skeletal remains with a post-mortem interval over 23 years. *Int. J. Legal Med.* **2021**, *135*, 457–463. [CrossRef] [PubMed]

85. Tufvesson, E.; Bjermer, L. Methodological improvements for measuring eicosanoids and cytokines in exhaled breath condensate. *Respir. Med.* **2014**, *108*, 1163–1168. [CrossRef] [PubMed]
88. Shekari, A.; Valipour, R.; Setareh, M.; Soltaninejad, K. Research Paper: Ultrasound-assisted liquid-liquid extraction for analyzing methadone in urine samples by gas chromatography-mass spectrometry. *Int. J. Med. Toxicol. Forensic Med.* 2020, 10, 29457. [CrossRef]

89. Shekari, A.; Forouzesh, M.; Valipour, R.; Fallah, F.; Shojaei, P. Validation and optimization of ultrasound-assisted dispersive liquid-liquid microextraction as a preparation method for detection of methadone in saliva with gas chromatography-mass spectrometry technique. *Adv. Pharm. Bull.* 2020, 10, 329–333. [CrossRef]

90. Chan, K.W.; Harun, H. Liquid chromatography tandem mass spectrometric method validation for the quantification of buprenorphine and norbuprenorphine in whole blood. *Aust. J. Forensic Sci.* 2017, 49, 186–200. [CrossRef]

91. Lin, Z.; Li, J.; Zhang, X.; Qiu, M.; Huang, Z.; Rao, Y. Ultrasound-assisted dispersive liquid-liquid microextraction for the determination of seven recreational drugs in human whole blood using gas chromatography-mass spectrometry. *J. Chromatogr. B Anal. Technol. Biomed. Life Sci.* 2017, 1046, 177–184. [CrossRef] [PubMed]

92. Farquharson, S.; Dana, K.; Shende, C.; Gladding, Z.; Newcomb, J.; Dascher, J.; Arias, A.J. Rapid identification of buprenorphine in patient saliva. *J. Anal. Bioanal. Technol.* 2017, 8, 1–5. [CrossRef] [PubMed]

93. Prosen, H.; Fontanals, N.; Borrull, F.; Marcé, R.M. Determination of seven drugs of abuse and their metabolites in surface and wastewater using solid-phase extraction coupled to liquid chromatography with high-resolution mass spectrometry. *J. Sep. Sci.* 2017, 40, 3621–3631. [CrossRef] [PubMed]

94. Habibi, B.; Rostamkhani, S.; Hamidi, M. Magnetic molecularly imprinted polymer nanoparticles for dispersive micro solid-phase extraction and determination of buprenorphine in human urine samples by HPLC-FL. *J. Iran. Chem. Soc.* 2018, 15, 1569–1580. [CrossRef]

95. Farmany, A.; Shamsara, M.; Mahdavi, H. Enhanced electrochemical biosensing of buprenorphine opioid drug by highly stabilized magnetic nanocrystals. *Sens. Actuators B* 2017, 239, 279–285. [CrossRef]

96. Cui, X.; Ni, C.; Liang, C.; Gong, F.; Wang, R.; Chen, G.; Zhang, Y. Screening and quantitation of forty-six drugs of abuse and toxic compounds in human whole blood by capillary electrophoresis: Application to forensic cases. *Microchem. J.* 2019, 144, 403–410. [CrossRef]